Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study-Reference-Cited by-同舟云学术

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

Published:2014-04 Issue:4 Volume:15 Page:436-444
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Larkin James,Del Vecchio Michele,Ascierto Paolo A,Krajsova Ivana,Schachter Jacob,Neyns Bart,Espinosa Enrique,Garbe Claus,Sileni Vanna Chiarion,Gogas Helen,Miller Wilson H,Mandalà Mario,Hospers Geke A P,Arance Ana,Queirolo Paola,Hauschild Axel,Brown Michael P,Mitchell Lada,Veronese Luisa,Blank Christian U

Publisher

Elsevier BV

Subject

Oncology

Reference14 articles.

1. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline;Garbe;Eur J Cancer,2010

2. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials;Korn;J Clin Oncol,2008

3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

4. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib;Sosman;N Engl J Med,2012

5. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

Cited by 234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plattenepithelkarzinom der Haut;hautnah;2024-07-09

2. Unsupervised Analysis Reveals the Involvement of Key Immune Response Genes and the Matrisome in Resistance to BRAF and MEK Inhibitors in Melanoma;Cancers;2024-06-24

3. Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials;JAMA Dermatology;2024-06-01

4. Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?;International Journal of Drug Discovery and Pharmacology;2024-05-23

5. Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab;British Journal of Cancer;2024-05-20